B-intervention	0	10	Ultrasound
I-intervention	11	17	guided
I-intervention	18	25	erector
I-intervention	26	32	spinae
I-intervention	33	38	plane
I-intervention	39	44	block
O	45	52	reduces
O	53	66	postoperative
O	67	73	opioid
O	74	85	consumption
O	86	95	following
O	96	102	breast
O	103	110	surgery
O	110	111	:
O	112	113	A
O	114	124	randomized
O	125	135	controlled
O	136	141	study
O	141	142	.

O	143	145	To
O	146	154	evaluate
O	155	158	the
O	159	168	analgesic
O	169	175	effect
O	176	178	of
O	179	189	ultrasound
O	189	190	-
O	190	196	guided
O	197	204	erector
O	205	211	spinae
O	212	217	plane
O	218	219	(
O	219	222	ESP
O	222	223	)
O	224	229	block
O	230	232	in
O	233	239	breast
O	240	246	cancer
O	247	254	surgery
O	254	255	.

O	256	266	Randomized
O	267	277	controlled
O	277	278	,
O	279	285	single
O	285	286	-
O	286	293	blinded
O	294	299	trial
O	299	300	.

O	301	310	Operating
O	311	315	room
O	315	316	.

B-total-participants	317	322	Fifty
O	323	326	ASA
O	327	328	I
O	328	329	-
O	329	331	II
O	332	340	patients
B-age	341	345	aged
I-age	346	348	25
I-age	348	349	-
I-age	349	351	65
O	352	355	and
B-eligibility	356	365	scheduled
I-eligibility	366	369	for
I-eligibility	370	378	elective
I-eligibility	379	385	breast
I-eligibility	386	392	cancer
I-eligibility	393	400	surgery
O	401	405	were
O	406	414	included
O	415	417	in
O	418	421	the
O	422	427	study
O	427	428	.

O	429	437	Patients
O	438	442	were
O	443	453	randomized
O	454	458	into
O	459	462	two
O	463	469	groups
O	469	470	,
O	471	474	ESP
O	475	478	and
B-control	479	486	control
O	486	487	.

O	488	494	Single
O	494	495	-
O	495	499	shot
O	500	510	ultrasound
O	511	512	(
O	512	514	US
O	514	515	)
O	515	516	-
O	516	522	guided
O	523	526	ESP
O	527	532	block
O	533	537	with
O	538	540	20
O	541	543	ml
O	544	545	0
O	545	546	.
O	546	548	25
O	548	549	%
O	550	561	bupivacaine
O	562	564	at
O	565	568	the
O	569	571	T4
O	572	581	vertebral
O	582	587	level
O	588	591	was
O	592	601	performed
O	602	616	preoperatively
O	617	619	to
O	620	623	all
O	624	632	patients
O	633	635	in
O	636	639	the
O	640	643	ESP
O	644	649	group
O	649	650	.

O	651	654	The
O	655	662	control
O	663	668	group
O	669	677	received
O	678	680	no
O	681	693	intervention
O	693	694	.

O	695	703	Patients
O	704	706	in
O	707	711	both
O	712	718	groups
O	719	723	were
O	724	732	provided
O	733	737	with
O	738	749	intravenous
O	750	757	patient
O	757	758	-
O	758	768	controlled
O	769	778	analgesia
O	779	785	device
O	786	796	containing
O	797	805	morphine
O	806	809	for
O	810	823	postoperative
O	824	833	analgesia
O	833	834	.

O	835	843	Morphine
O	844	855	consumption
O	856	859	and
O	860	867	numeric
O	868	874	rating
O	875	880	scale
O	881	882	(
O	882	885	NRS
O	885	886	)
O	887	891	pain
O	892	898	scores
O	899	903	were
O	904	912	recorded
O	913	915	at
O	916	917	1
O	917	918	,
O	919	920	6
O	920	921	,
O	922	924	12
O	925	928	and
O	929	931	24
O	932	933	h
O	934	949	postoperatively
O	949	950	.

B-outcome	951	959	Morphine
I-outcome	960	971	consumption
I-outcome	972	974	at
I-outcome	975	988	postoperative
I-outcome	989	994	hours
O	995	996	1
O	996	997	,
O	998	999	6
O	999	1000	,
O	1001	1003	12
O	1004	1007	and
O	1008	1010	24
O	1011	1020	decreased
O	1021	1034	significantly
O	1035	1037	in
O	1038	1041	the
O	1042	1045	ESP
O	1046	1051	group
O	1052	1053	(
O	1053	1054	p
O	1055	1056	<
O	1057	1058	0
O	1058	1059	.
O	1059	1061	05
O	1062	1065	for
O	1066	1070	each
O	1071	1075	time
O	1076	1084	interval
O	1084	1085	)
O	1085	1086	.

B-outcome	1087	1092	Total
I-outcome	1093	1101	morphine
I-outcome	1102	1113	consumption
O	1114	1123	decreased
O	1124	1126	by
O	1127	1129	65
O	1129	1130	%
B-outcome	1131	1133	at
I-outcome	1134	1136	24
I-outcome	1137	1138	h
O	1139	1147	compared
O	1148	1150	to
O	1151	1154	the
O	1155	1162	control
O	1163	1168	group
O	1169	1170	(
B-iv-cont-mean	1170	1171	5
I-iv-cont-mean	1171	1172	.
I-iv-cont-mean	1172	1174	76
O	1175	1176	±
B-iv-cont-sd	1177	1178	3
I-iv-cont-sd	1178	1179	.
I-iv-cont-sd	1179	1180	8
I-iv-cont-sd	1181	1183	mg
O	1184	1186	vs
B-cv-cont-mean	1187	1189	16
I-cv-cont-mean	1189	1190	.
I-cv-cont-mean	1190	1191	6
O	1192	1193	±
B-cv-cont-sd	1194	1195	6
I-cv-cont-sd	1195	1196	.
I-cv-cont-sd	1196	1198	92
I-cv-cont-sd	1199	1201	mg
O	1201	1202	)
O	1202	1203	.

O	1204	1209	There
O	1210	1213	was
O	1214	1216	no
O	1217	1230	statistically
O	1231	1242	significant
O	1243	1253	difference
O	1254	1261	between
O	1262	1265	the
O	1266	1272	groups
O	1273	1275	in
O	1276	1281	terms
O	1282	1284	of
B-outcome	1285	1288	NRS
I-outcome	1289	1295	scores
O	1295	1296	.

O	1297	1300	Our
O	1301	1306	study
O	1307	1315	findings
O	1316	1320	show
O	1321	1325	that
O	1326	1328	US
O	1328	1329	-
O	1329	1335	guided
O	1336	1339	ESP
O	1340	1345	block
O	1346	1354	exhibits
O	1355	1356	a
O	1357	1368	significant
O	1369	1378	analgesic
O	1379	1385	effect
O	1386	1388	in
O	1389	1397	patients
O	1398	1408	undergoing
O	1409	1415	breast
O	1416	1422	cancer
O	1423	1430	surgery
O	1430	1431	.

O	1432	1439	Further
O	1440	1447	studies
O	1448	1457	comparing
O	1458	1467	different
O	1468	1476	regional
O	1477	1487	anesthesia
O	1488	1498	techniques
O	1499	1502	are
O	1503	1509	needed
O	1510	1512	to
O	1513	1521	identify
O	1522	1525	the
O	1526	1533	optimal
O	1534	1543	analgesia
O	1544	1553	technique
O	1554	1557	for
O	1558	1562	this
O	1563	1568	group
O	1569	1571	of
O	1572	1580	patients
O	1580	1581	.
